Latest Advances

  • Condition: Diffuse Large B-Cell Lymphoma
  • Journal: Blood advances
  • Treatment Used: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
  • Number of Patients: 210
  • Published —
The study researched the use of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone for treating diffuse large B-cell lymphoma.
  • Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
  • Journal: Blood advances
  • Treatment Used: Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
  • Number of Patients: 1418
  • Published —
This study assessed progression-free survival (PFS) and overall survival (OS) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) receiving obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP).
  • Condition: B-cell Malignancies, Mantle cell lymphoma, and Multiple Myeloma
  • Journal: Frontiers in immunology
  • Treatment Used: CAR T-Cell Therapy
  • Number of Patients: 0
  • Published —
This article discusses the use of CAR T-cell therapy in the treatment of patients with B-cell malignancies, mantle cell lymphoma, and multiple myeloma.
  • Condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Journal: Journal of hematology & oncology
  • Treatment Used: CD19-Targeted Chimeric Antigen Receptor T (CAR T) Cell Therapy
  • Number of Patients: 6
  • Published —
The study researched the use of CD19-targeted chimeric antigen receptor T (CAR T) cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
  • Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
  • Journal: Blood advances
  • Treatment Used: R-CHOP vs. CHOP Combined with Dose-Dense Rituximab (RW-CHOP)
  • Number of Patients: 421
  • Published —
This study compared R-CHOP with CHOP plus dose-dense weekly rituximab (RW-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL).
  • Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
  • Journal: Blood
  • Treatment Used: Venetoclax plus R-CHOP as First-Line Treatment
  • Number of Patients: 206
  • Published —
This study assessed the safety and effectiveness of venetoclax with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL).
  • Condition: Relapsed or Refractory B-Cell Lymphoma
  • Journal: Cancer science
  • Treatment Used: Tazemetostat
  • Number of Patients: 7
  • Published —
The study researched the use of tazemetostat for treating relapsed or refractory B-cell lymphoma.
  • Condition: Synchronous Retroperitoneal Tumor and Ovarian Mature Teratoma
  • Journal: Gan to kagaku ryoho. Cancer & chemotherapy
  • Treatment Used: Laparoscopic Surgery
  • Number of Patients: 1
  • Published —
This study reports of a 72 year old woman with retroperitoneal and ovarian tumors who was treated with laparoscopic surgery.
  • Condition: Primary Diffuse Large B Cell Lymphoma of Lactating Left Breast
  • Journal: Annali italiani di chirurgia
  • Treatment Used: Segmental Mastectomy, CHOP, and Rituximab
  • Number of Patients: 1
  • Published —
This case report describes a 31-year-old female diagnosed with a primary diffuse large B cell lymphoma of the lactating left breast treated with segmental mastectomy, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), and two cycles of monoclonal antibody rituximab.
  • Condition: Diffuse Large B-cell Lymphoma
  • Journal: Medical oncology (Northwood, London, England)
  • Treatment Used: R-CHOP Standard Chemotherapy plus Lansoprazole Versus plus Famotidine
  • Number of Patients: 60
  • Published —
In this study, researchers sought to determine the best secondary treatment for diffuse large B-cell lymphoma.
  • Condition: Relapsed Diffuse Large B-Cell Lymphoma
  • Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • Treatment Used: Programmed Cell Death-1 Inhibitor with Rituximab
  • Number of Patients: 22
  • Published —
The study researched the outcomes of Programmed cell death-1 inhibitor combined with rituximab for patients with relapsed diffuse large B-cell lymphoma.
  • Condition: Diffuse Large B Cell Lymphoma
  • Journal: BMC cancer
  • Treatment Used: Chemotherapy
  • Number of Patients: 8207
  • Published —
The study researched the outcomes of various chemotherapies for treating diffuse large B cell lymphoma.
Showing 1-12 of 216